- Home
- GBX vs PHVS Comparison
GBX vs PHVS Comparison
Compare GBX & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBX
- PHVS
- Stock Information
- Founded
- GBX 1974
- PHVS 2015
- Country
- GBX United States
- PHVS Switzerland
- Employees
- GBX N/A
- PHVS N/A
- Industry
- GBX Railroads
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- GBX Industrials
- PHVS Health Care
- Exchange
- GBX Nasdaq
- PHVS Nasdaq
- Market Cap
- GBX 1.4B
- PHVS 1.3B
- IPO Year
- GBX N/A
- PHVS 2021
- Fundamental
- Price
- GBX $47.15
- PHVS $23.05
- Analyst Decision
- GBX Hold
- PHVS Buy
- Analyst Count
- GBX 2
- PHVS 6
- Target Price
- GBX $59.50
- PHVS $36.67
- AVG Volume (30 Days)
- GBX 268.1K
- PHVS 119.1K
- Earning Date
- GBX 10-22-2025
- PHVS 08-12-2025
- Dividend Yield
- GBX 2.74%
- PHVS N/A
- EPS Growth
- GBX 88.14
- PHVS N/A
- EPS
- GBX 7.10
- PHVS N/A
- Revenue
- GBX $3,533,700,000.00
- PHVS N/A
- Revenue This Year
- GBX N/A
- PHVS N/A
- Revenue Next Year
- GBX N/A
- PHVS N/A
- P/E Ratio
- GBX $6.57
- PHVS N/A
- Revenue Growth
- GBX 0.70
- PHVS N/A
- 52 Week Low
- GBX $37.77
- PHVS $11.51
- 52 Week High
- GBX $71.06
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- GBX 52.50
- PHVS 55.97
- Support Level
- GBX $45.44
- PHVS $21.41
- Resistance Level
- GBX $47.50
- PHVS $24.52
- Average True Range (ATR)
- GBX 1.02
- PHVS 1.34
- MACD
- GBX 0.14
- PHVS -0.15
- Stochastic Oscillator
- GBX 69.23
- PHVS 47.24
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of its revenue from the United States.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.